





RealRate

# PHARMACEUTICAL 2017

Clovis Oncology Inc.  
Rank 236 of 292



The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Clovis Oncology Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -97%, being 100% points below the market average of 2.9%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 279,410           |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 78,239            |
| Liabilities, Current                        | 65,597            |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 2,468             |
| Other Compr. Net Income                     | -120              |
| Other Expenses                              | 47,617            |
| Other Liabilities                           | 302,594           |
| Other Net Income                            | -8,438            |
| Other Revenues                              | 78                |
| Property and Equipment                      | 4,440             |
| Research and Development                    | 252,429           |
| Selling, General and Administrative Expense | 40,731            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 364,557           |
| Liabilities              | 368,191           |
| Expenses                 | 340,777           |
| Revenues                 | 78                |
| Stockholders Equity      | -3,634            |
| Net Income               | -349,137          |
| Comprehensive Net Income | -349,197          |
| Economic Capital Ratio   | -97%              |